Trinity Biotech FRAUD- they purchased MarDx

[kathleen]

To: Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
len...@courant.com, michae...@po.state.ct.us,
con...@po.state.ct.us, executiv...@nytimes.com, managing-
edi...@nytimes.com, news...@nytimes.com, the-...@nytimes.com,
biz...@nytimes.com, for...@nytimes.com, me...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, ubi...@courant.com, ma...@concentric.net,
camp...@courant.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, hor...@courant.com,
commissi...@po.state.ct.us, cohen...@aol.com,
FalN...@aol.com, brans...@comcast.net, vts...@comcast.net,
o...@po.state.ct.us, da...@davila-dilzer.com,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, hor...@courant.com,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, thomas...@usdoj.gov, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
sidney_b...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov

Subject: Trinity Biotech FRAUD- they purchased MarDx

Date: Jan 24, 2008 10:32 PM

ADVERTISEMENT BELOW
==============================

The only kind of people who tend to test positive to this VLSE method
(the "C6
peptide test") are people who have Steere's kind of Lyme; the
genetically
linked arthritis in a knee:
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=steere+AC%5BAuthor%5D+AND+HLA%5BAll+Fields%5D&WebEnv=0OgoyokjwpZR_X6bRae6de1Mewuq5VzjkL-G5niBOdazXb79CS0kmjRvSiNoYGNoXQQyas3yNAgUr%4025631EEC6FE066A0_0067SID&WebEnvRq=1
or explained with graphics, here:
http://www.actionlyme.org/CRYMEDISEASE_CHP3.htm

Trinity Biotech bought MarDx. the company that was fraudulently given
Allen Steere-positive
blood (see the difference in the Western Blots, here):
http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm
to falsely state that the Steere method was good, as they had already
been given
the contracts for both vaccine trials before Dearborn ever even took
place

If you look carefully at this report you will see that this ImmuLyme
trial was started
in March 1994, using MarDx Western Blot strips:
http://content.nejm.org/cgi/reprint/339/4/216.pdf
Dearborn did not happen until 7 months later in October, 1994.
In between the FDA held a meeting in which Ray Dattwyler suggested
using serial
Western Blots to test the vaccines' efficacies, which was the old, pre-
Dearborn
method to test for Lyme (perform sequential Western Blots to look for
new IgM antibodies):
http://www.actionlyme.org/DEARBORN_WHO_SAID_WHAT.htm
http://www.actionlyme.org/Dattwyler_Luft_Bb_DNA_in_CSF.htm

So, stay away from Trinity or Jeremy Gray or Susan O'Connell in the
UK, since
they're part of the Lyme cabal, the ALDF.com and the EUCALB.
O'Connell
is a tight-lipped B-word, and the UK NHS flips when you call them and
question them
about the testing for Lyme. There is reason to believe they're
associated with
the shenanigans at Porton Down, who vie for the Global Sloppy
Bioweapons Scientists
with the USA. (We're not sure which is worse; UK gets caught more
often in
their sloppy bioweapons work, but on the other hand, Lyme may have
been an accidental
release, especially since OspA has the same basic structure as two of
the primary
HIV ligands:
http://www.actionlyme.org/DURHAM_BUSH_CRIME.htm


Use the old Bowen Lab:
http://centralfloridaresearch.com/lab/index.php?option=com_content&task=view&id=18&Itemid=33
This is a test using immunofluorescing antibodies from modified from
goat sera,
where the goats were infected with 15 strains of borrelia.


The Lyme bad guys are acting very frickin hysterical, lately. They're
trying
like hell to say Lyme is only a knee disease, since that's their
defense against
their first crime, LYMErix- the vaccine that changed the definition of
the disease;
a vaccine against autoimmune arthritis in a knee, about which
SmithKline said at
the 2001 FDA meeting "*WE* never said Lyme arthritis in a knee was
caused by
an autoimmune disease; we think it is caused by persisting infection."

Well, why give people a vaccine that caused an autoimmune disease?

At the same time, Yale told all the trial administrators not to report
anything
that was not a bad knee in response to LYMErix:
http://www.actionlyme.org/Bull_Lewis.htm
http://www.actionlyme.org/SCHOEN_INSTRUCTING_DOCS_TO_BLOW_OFF_LYMERIX_INJUREES.htm

This is more of the same baloney. Verify independently if Trinity
bought Mardx.
We would like to know who they were and how they ended up with Steere-
positive blood
to assess Steere's proposal:
http://www.actionlyme.org/DEARBORN_WHO_APPROVED.htm
None of the other invited labs agreed with Steere- not by a long
shot. Even Gary
Wormser reported that Steere's proposal for the interpretation of
Western Blots
detected only 9/59 cases, or was 15% accurate or missed 85% of the
cases:
http://www.actionlyme/org/HOW_RICO_WILL_BE_CHARGED.htm


People have to take matters into their own hands since we have no
Justice Department
and the entire DHHS is corrupt:
http://www.actionlyme.org/CUSTOMS.htm
For going on 9 years we have been reporting and watching in
stupification (if that
were possible, given we're already stupified as shown by the
replapsing brain
scans:
http://www.actionlyme.org/JAMES_PHILLIPS_HOMEPAGE.htm )
this incompetent circus:
http://www.actionlyme.org/Actionlyme_History.htm

And I don't recall America thanking us demented and sick Lyme victims
for getting
rid of that dangerous Lyme vaccine...
http://www.fda.gov/OHRMS/DOCKETS/ac/01/slides/3680s2.htm


Kathleen M. Dickson
================
http://money.cnn.com/news/newsfeeds/articles/marketwire/0352443.htm
Trinity Biotech Announces the Launch of New Lyme Products for the
European Market
Marketwire
January 24, 2008: 08:00 AM EST

Trinity Biotech plc (NASDAQ: TRIB), a leading developer and
manufacturer of diagnostic
products for the point-of-care and clinical laboratory markets, today
announced
the launch of its new Lyme Enzyme Immunoassay (EIA) products
specifically designed
for the European market.

The new products, the Trinity Biotech EU Lyme IgG + VlsE EIA and the
EU Lyme IgM
EIA are designed for use as screening assays in clinical laboratories.
They are
qualitative serological tests for the detection of IgG and IgM
antibodies to the
most prevalent and clinically important Borrelia species in Europe,
i.e. Borrerlia
afzelii, Borrelia garinii, and Borrelia burgdorferi. The addition of
VlsE to the
product significantly boosts sensitivity of the assay. These new
products complete
Trinity Biotech's product offering for Lyme Disease in Europe,
complementing
the existing EU Lyme Western Blot confirmatory assays.

Borrelia species cause Lyme Disease in humans following transmission
via a tick
bite. Lyme Disease is the most common tick-borne disease in the EU.
The most frequent
symptoms include skin rash, diffuse flu-like reaction and joint pains.
The characteristic
rash is not always present making diagnosis more difficult. If
untreated or inadequately
treated, neurological, cardiac, or serious joint abnormalities may
follow.

Eurosurveillance (www.eurosurveillance.org) reports that the incidence
of Lyme Disease
is on the increase across Europe with particularly high increases seen
in Northern
and Eastern Europe. The continued expansion of this market segment is
driven by
factors that increase exposure to ticks. Greater participation in
outdoor activities
such as hiking, hunting and fishing and recent milder winters have
contributed to
the proliferation of tick numbers with a consequent increased
incidence of Lyme
Disease.

"Due to the diverse nature of clinical symptoms, diagnosis of Lyme
Disease
is difficult, thus making confirmation with a diagnostic assay always
advisable.
The excellent performance of Trinity's new EIAs in combination with
the existing
EU Lyme Western Blot products will provide invaluable information to
clinicians
to aid diagnosis," commented Brendan K. Farrell CEO of Trinity
Biotech. "Trinity
Biotech is the global leader in Lyme Disease diagnostics. The launch
of our new
EU Lyme EIA assays extends our product offering to European customers.
Trinity now
offers both screening and confirmatory assays to all markets, thus
reinforcing its
number one position for Lyme detection in the world."

Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems,
including both reagents and instrumentation, for the point-of-care and
clinical
laboratory segments of the diagnostic market. The products are used to
detect infectious
diseases and blood coagulation disorders, and to quantify the level of
Haemoglobin
A1c and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech
sells direct in the United States, Germany, France and the U.K. and
through a network
of international distributors and strategic partners in over 75
countries worldwide.
For further information please see the Company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the
"safe harbor"
provision of the Private Securities Litigation Reform Act of 1995.
Investors are
cautioned that such forward-looking statements involve risks and
uncertainties including,
but not limited to, the results of research and development efforts,
the effect
of regulation by the United States Food and Drug Administration and
other agencies,
the impact of competitive products, product development
commercialization and technological
difficulties, and other risks detailed in the Company's periodic
reports filed
with the Securities and Exchange Commission.

Contact :
Trinity Biotech plc
Brendan Farrell
CEO
(353)-1-2769800
E-mail: Email Contact